🇺🇸 FDA
Patent

US 7557207

Spiro 2,4-pyrimidinediamine compounds and their uses

granted A61PA61P1/04A61P11/00

Quick answer

US patent 7557207 (Spiro 2,4-pyrimidinediamine compounds and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P1/04, A61P11/00, A61P17/02, A61P19/02